Biomarker Targeted Stimulation for Epileptiform Events (BTSEE)

November 12, 2026 updated by: Cadence Neuroscience

Safety and Effectiveness of Biomarker Targeted Stimulation in Epilepsy

This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • California
      • Palo Alto, California, United States, 94304
        • Recruiting
        • Lucile Packard Children's Hospital Stanford
        • Contact:
        • Principal Investigator:
          • Ann Hyslop Segeren, MD
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic
        • Contact:
        • Principal Investigator:
          • Nicholas Gregg, MD
    • Texas
      • Fort Worth, Texas, United States, 76104
        • Recruiting
        • Cook Children's Medical Center
        • Contact:
        • Principal Investigator:
          • M. Scott Perry, MD
    • Washington
      • Seattle, Washington, United States, 98105
        • Recruiting
        • Seattle Children's Hospital
        • Principal Investigator:
          • Hannah Goldstein, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Subject is greater than or equal to 7 years of age.
  2. Subject has focal onset seizures.
  3. Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
  4. Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
  5. Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
  6. For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
  7. Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
  8. A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
  9. Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
  10. Subject has had a brain MRI epilepsy evaluation within the past two years.
  11. Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.

Exclusion Criteria:

  1. Subject has a history of substance abuse within the preceding two years.

  2. Subject participated in another drug or device trial that may confound study results within the preceding 30 days.

  3. Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.

  4. Subject has anatomy that may interfere with electrode placement.

  5. Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.

  6. Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.

  7. Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.

  8. Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).

  9. Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.

  10. Subject has primary generalized seizures.

  11. Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:

    1. The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
    2. Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
  12. Subject, in the opinion of the Investigator, would be a poor study candidate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment

Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse event rate
Time Frame: Intervals through 7, 12, and 24 months post-implant

Determine adverse event rate, including adverse device effects and serious adverse events

Intervals through 7, 12, and 24 months post-implant

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Seizure frequency
Time Frame: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.

Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline.

Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
Neurocognitive testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Depression testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Anxiety testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Quality of life testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Sleep testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Seizure severity testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Caregiver burden testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Suicidality risk testing
Time Frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

November 1, 2030

Study Registration Dates

First Submitted

May 9, 2024

First Submitted That Met QC Criteria

May 17, 2024

First Posted (Actual)

May 22, 2024

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CAD2004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.